RedHill Biopharma Ltd. filed a prospectus supplement on June 29, 2026, to increase the maximum aggregate offering amount of American Depositary Shares (ADS) under its existing At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC. RedHill Biopharma Ltd. is a biopharmaceutical company focused on the development and commercialization of medicines for gastrointestinal diseases.
